{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T17:32:54Z","timestamp":1790530374016,"version":"4.1.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Science and Technology Planning Project of Guangzhou City","award":["202201020582"],"award-info":[{"award-number":["202201020582"]}]},{"name":"the Scientific Research Project of Ministry of Education of Liaoning Province","award":["LJKZZ20220100"],"award-info":[{"award-number":["LJKZZ20220100"]}]},{"name":"the Interdisciplinary Research Cooperation Project Team Funding of Dalian Medical University Planning and research category","award":["JCHZ2023001"],"award-info":[{"award-number":["JCHZ2023001"]}]},{"name":"the United Foundation for Dalian Institute of Chemical Physics & Chinese Academy of Sciences and the Second Hospital of DaliarMedical University","award":["DMU-2\uff06DICP UN202304"],"award-info":[{"award-number":["DMU-2\uff06DICP UN202304"]}]},{"name":"\u201c1+X \u201dprogram for Clinical Competency enhancement\u2013Clinical Technical Level Improvement Project, The Second Hospital of Dalian Medical University","award":["2022LCJSGC16"],"award-info":[{"award-number":["2022LCJSGC16"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02484-5","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T19:05:09Z","timestamp":1747076709000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Development of a machine learning-based predictive risk model combining fatty acid metabolism and ferroptosis for immunotherapy response and prognosis in prostate cancer"],"prefix":"10.1007","volume":"16","author":[{"given":"Zhenwei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuren","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongxiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuqiu","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofu","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"2484_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"2484_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2013.05.017","volume":"18","author":"E Currie","year":"2013","unstructured":"Currie E, Schulze A, Zechner R, Walther TC, Farese RV. Cellular fatty acid metabolism and cancer. Cell Metab. 2013;18:153\u201361. https:\/\/doi.org\/10.1016\/j.cmet.2013.05.017.","journal-title":"Cell Metab"},{"key":"2484_CR3","doi-asserted-by":"publisher","first-page":"897","DOI":"10.7150\/ijbs.81609","volume":"19","author":"Y Liu","year":"2023","unstructured":"Liu Y, Sun Y, Guo Y, Shi X, Chen X, Feng W, Wu LL, et al. An overview: the diversified role of mitochondria in cancer metabolism. Int J Biol Sci. 2023;19:897\u2013915. https:\/\/doi.org\/10.7150\/ijbs.81609.","journal-title":"Int J Biol Sci"},{"key":"2484_CR4","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s11912-022-01223-1","volume":"24","author":"Y Luo","year":"2022","unstructured":"Luo Y, Wang H, Liu B, Wei J. Fatty acid metabolism and cancer immunotherapy. Curr Oncol Rep. 2022;24:659\u201370. https:\/\/doi.org\/10.1007\/s11912-022-01223-1.","journal-title":"Curr Oncol Rep"},{"key":"2484_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41416-019-0650-z","volume":"122","author":"N Koundouros","year":"2020","unstructured":"Koundouros N, Poulogiannis G. Reprogramming of fatty acid metabolism in cancer. Br J Cancer. 2020;122:4\u201322. https:\/\/doi.org\/10.1038\/s41416-019-0650-z.","journal-title":"Br J Cancer"},{"key":"2484_CR6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jhep.2024.03.016","volume":"81","author":"L Xu","year":"2024","unstructured":"Xu L, Zhang Y, Lin Z, Deng X, Ren X, Huang M, Li S, et al. FASN-mediated fatty acid biosynthesis remodels immune environment in Clonorchis sinensis infection-related intrahepatic cholangiocarcinoma. J Hepatol. 2024;81:265\u201377. https:\/\/doi.org\/10.1016\/j.jhep.2024.03.016.","journal-title":"J Hepatol"},{"key":"2484_CR7","doi-asserted-by":"publisher","DOI":"10.1172\/JCI141529","author":"H Ito","year":"2021","unstructured":"Ito H, Nakamae I, Kato J-Y, Yoneda-Kato N. Stabilization of fatty acid synthesis enzyme acetyl-CoA carboxylase 1 suppresses acute myeloid leukemia development. J Clin Investig. 2021. https:\/\/doi.org\/10.1172\/JCI141529.","journal-title":"J Clin Investig"},{"key":"2484_CR8","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41586-021-04049-2","volume":"599","author":"EC Lien","year":"2021","unstructured":"Lien EC, Westermark AM, Zhang Y, Yuan C, Li Z, Lau AN, Sapp KM, Wolpin BM, Heiden MGV. Low glycaemic diets alter lipid metabolism to influence tumour growth. Nature. 2021;599:302\u20137. https:\/\/doi.org\/10.1038\/s41586-021-04049-2.","journal-title":"Nature"},{"key":"2484_CR9","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1158\/1541-7786.MCR-20-0379","volume":"19","author":"Y Ma","year":"2021","unstructured":"Ma Y, Zhang X, Alsaidan OA, Yang X, Sulejmani E, Zha J, Beharry Z, et al. Long-chain Acyl-CoA synthetase 4-mediated fatty acid metabolism sustains androgen receptor pathway-independent prostate cancer. Mol Cancer Res MCR. 2021;19:124\u201335. https:\/\/doi.org\/10.1158\/1541-7786.MCR-20-0379.","journal-title":"Mol Cancer Res MCR"},{"key":"2484_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11110765","author":"H Xu","year":"2021","unstructured":"Xu H, Chen Y, Meng Gu, Liu C, Chen Qi, Zhan M, Wang Z. Fatty acid metabolism reprogramming in advanced prostate cancer. Metabolites. 2021. https:\/\/doi.org\/10.3390\/metabo11110765.","journal-title":"Metabolites"},{"key":"2484_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mc.23475","volume":"62","author":"Y Guo","year":"2023","unstructured":"Guo Y, Zheng Z, Mao S, Yang F, Wang R, Wang H, Liu Ji, et al. Metabolic-associated signature and hub genes associated with immune microenvironment and prognosis in bladder cancer. Mol Carcinog. 2023;62:185\u201399. https:\/\/doi.org\/10.1002\/mc.23475.","journal-title":"Mol Carcinog"},{"key":"2484_CR12","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13045-022-01392-3","volume":"15","author":"X Tong","year":"2022","unstructured":"Tong X, Tang R, Xiao M, Jin Xu, Wang W, Zhang Bo, Liu J, Xianjun Yu, Shi Si. Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research. J Hematol Oncol. 2022;15:174. https:\/\/doi.org\/10.1186\/s13045-022-01392-3.","journal-title":"J Hematol Oncol"},{"key":"2484_CR13","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1158\/0008-5472.CAN-23-1489","volume":"84","author":"RK Shrestha","year":"2024","unstructured":"Shrestha RK, Nassar ZD, Hanson AR, Iggo R, Townley SL, Dehairs J, Mah CY, et al. ACSM1 and ACSM3 regulate fatty acid metabolism to support prostate cancer growth and constrain ferroptosis. Can Res. 2024;84:2313\u201332. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-1489.","journal-title":"Can Res"},{"key":"2484_CR14","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1097\/CM9.0000000000002533","volume":"136","author":"K Ding","year":"2023","unstructured":"Ding K, Liu C, Li Li, Yang M, Jiang Na, Luo S, Sun L. Acyl-CoA synthase ACSL4: an essential target in ferroptosis and fatty acid metabolism. Chin Med J. 2023;136:2521\u201337. https:\/\/doi.org\/10.1097\/CM9.0000000000002533.","journal-title":"Chin Med J"},{"key":"2484_CR15","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.ccell.2022.02.003","volume":"40","author":"P Liao","year":"2022","unstructured":"Liao P, Wang W, Wang W, Kryczek I, Li X, Bian Y, Sell A, et al. CD8(+) T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. Cancer Cell. 2022;40:365-378.e6. https:\/\/doi.org\/10.1016\/j.ccell.2022.02.003.","journal-title":"Cancer Cell"},{"key":"2484_CR16","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.trecan.2023.03.003","volume":"9","author":"U Sen","year":"2023","unstructured":"Sen U, Coleman C, Sen T. Stearoyl coenzyme A desaturase-1: multitasker in cancer, metabolism, and ferroptosis. Trends Cancer. 2023;9:480\u20139. https:\/\/doi.org\/10.1016\/j.trecan.2023.03.003.","journal-title":"Trends Cancer"},{"key":"2484_CR17","doi-asserted-by":"publisher","first-page":"4765","DOI":"10.1038\/s41467-020-18565-8","volume":"11","author":"J-W Hao","year":"2020","unstructured":"Hao J-W, Wang J, Guo H, Zhao Y-Y, Sun H-H, Li Y-F, Lai X-Y, et al. CD36 facilitates fatty acid uptake by dynamic palmitoylation-regulated endocytosis. Nat Commun. 2020;11:4765. https:\/\/doi.org\/10.1038\/s41467-020-18565-8.","journal-title":"Nat Commun"},{"key":"2484_CR18","doi-asserted-by":"publisher","first-page":"32433","DOI":"10.1073\/pnas.2006828117","volume":"117","author":"J-Y Lee","year":"2020","unstructured":"Lee J-Y, Nam M, Son HY, Hyun K, Jang SY, Kim JW, Kim MW, et al. Polyunsaturated fatty acid biosynthesis pathway determines ferroptosis sensitivity in gastric cancer. Proc Natl Acad Sci USA. 2020;117:32433\u201342. https:\/\/doi.org\/10.1073\/pnas.2006828117.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2484_CR19","doi-asserted-by":"publisher","first-page":"1301452","DOI":"10.3389\/fimmu.2023.1301452","volume":"14","author":"Xi Huang","year":"2023","unstructured":"Huang Xi, Sun Y, Song J, Huang Y, Shi H, Qian A, Cao Y, Zhou Y, Wang Q. Prognostic value of fatty acid metabolism-related genes in colorectal cancer and their potential implications for immunotherapy. Front Immunol. 2023;14:1301452. https:\/\/doi.org\/10.3389\/fimmu.2023.1301452.","journal-title":"Front Immunol"},{"key":"2484_CR20","doi-asserted-by":"publisher","first-page":"843515","DOI":"10.3389\/fimmu.2022.843515","volume":"13","author":"Y Tang","year":"2022","unstructured":"Tang Y, Tian W, Xie J, Zou Y, Wang Z, Li N, Zeng Y, et al. Prognosis and dissection of immunosuppressive microenvironment in breast cancer based on fatty acid metabolism-related signature. Front Immunol. 2022;13:843515. https:\/\/doi.org\/10.3389\/fimmu.2022.843515.","journal-title":"Front Immunol"},{"key":"2484_CR21","doi-asserted-by":"publisher","first-page":"e71880","DOI":"10.7554\/eLife.71880","volume":"11","author":"C Yang","year":"2022","unstructured":"Yang C, Zhang H, Chen M, Wang S, Qian R, Zhang L, Huang X, et al. A survey of optimal strategy for signature-based drug repositioning and an application to liver cancer. eLife. 2022;11:e71880. https:\/\/doi.org\/10.7554\/eLife.71880.","journal-title":"eLife"},{"key":"2484_CR22","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41568-020-0290-x","volume":"20","author":"F Mart\u00ednez-Jim\u00e9nez","year":"2020","unstructured":"Mart\u00ednez-Jim\u00e9nez F, Mui\u00f1os F, Sent\u00eds I, Deu-Pons J, Reyes-Salazar I, Arnedo-Pac C, Mularoni L, et al. A compendium of mutational cancer driver genes. Nat Rev Cancer. 2020;20:555\u201372. https:\/\/doi.org\/10.1038\/s41568-020-0290-x.","journal-title":"Nat Rev Cancer"},{"key":"2484_CR23","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","volume":"19","author":"AR Moore","year":"2020","unstructured":"Moore AR, Rosenberg SC, McCormick F, Malek S. RAS-targeted therapies: is the undruggable drugged? Nature reviews. Drug Discov. 2020;19:533\u201352. https:\/\/doi.org\/10.1038\/s41573-020-0068-6.","journal-title":"Drug Discov"},{"key":"2484_CR24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI154943","author":"MR Waarts","year":"2022","unstructured":"Waarts MR, Stonestrom AJ, Park YC, Levine RL. Targeting mutations in cancer. J Clin Investig. 2022. https:\/\/doi.org\/10.1172\/JCI154943.","journal-title":"J Clin Investig"},{"key":"2484_CR25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-021-03634-9","volume":"596","author":"A Rao","year":"2021","unstructured":"Rao A, Barkley D, Fran\u00e7a GS, Yanai I. Exploring tissue architecture using spatial transcriptomics. Nature. 2021;596:211\u201320. https:\/\/doi.org\/10.1038\/s41586-021-03634-9.","journal-title":"Nature"},{"key":"2484_CR26","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.tips.2018.02.001","volume":"39","author":"EN Chini","year":"2018","unstructured":"Chini EN, Chini CCS, Netto JME, de Oliveira GC, van Schooten W. The pharmacology of CD38\/NADase: an emerging target in cancer and diseases of aging. Trends Pharmacol Sci. 2018;39:424\u201336. https:\/\/doi.org\/10.1016\/j.tips.2018.02.001.","journal-title":"Trends Pharmacol Sci"},{"key":"2484_CR27","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.2217\/fon-2020-0401","volume":"16","author":"Y Li","year":"2020","unstructured":"Li Y, Yang R, Chen L, Sufang Wu. CD38 as an immunomodulator in cancer. Future Oncol. 2020;16:2853\u201361. https:\/\/doi.org\/10.2217\/fon-2020-0401.","journal-title":"Future Oncol"},{"key":"2484_CR28","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1158\/1541-7786.MCR-17-0526","volume":"16","author":"JP Chmielewski","year":"2018","unstructured":"Chmielewski JP, Bowlby SC, Wheeler FB, Shi L, Sui G, Davis AL, Howard TD, et al. CD38 inhibits prostate cancer metabolism and proliferation by reducing cellular NAD(+) pools. Mol Cancer Res MCR. 2018;16:1687\u2013700. https:\/\/doi.org\/10.1158\/1541-7786.MCR-17-0526.","journal-title":"Mol Cancer Res MCR"},{"key":"2484_CR29","doi-asserted-by":"publisher","first-page":"890402","DOI":"10.3389\/fmolb.2022.890402","volume":"9","author":"M Kanayama","year":"2022","unstructured":"Kanayama M, Luo J. CD38-induced apoptosis and mitochondrial damage is restored by nicotinamide in prostate cancer. Front Mol Biosci. 2022;9:890402. https:\/\/doi.org\/10.3389\/fmolb.2022.890402.","journal-title":"Front Mol Biosci"},{"key":"2484_CR30","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.eururo.2014.05.004","volume":"66","author":"EA Klein","year":"2014","unstructured":"Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol. 2014;66:550\u201360. https:\/\/doi.org\/10.1016\/j.eururo.2014.05.004.","journal-title":"Eur Urol"},{"key":"2484_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.eururo.2015.05.042","volume":"69","author":"AE Ross","year":"2016","unstructured":"Ross AE, Johnson MH, Yousefi K, Davicioni E, Netto GJ, Marchionni L, Fedor HL, et al. Tissue-based genomics augments post-prostatectomy risk stratification in a natural history cohort of intermediate- and high-risk men. Eur Urol. 2016;69:157\u201365. https:\/\/doi.org\/10.1016\/j.eururo.2015.05.042.","journal-title":"Eur Urol"},{"key":"2484_CR32","doi-asserted-by":"publisher","first-page":"e66855","DOI":"10.1371\/journal.pone.0066855","volume":"8","author":"N Erho","year":"2013","unstructured":"Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, Bergstralh EJ, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS ONE. 2013;8:e66855. https:\/\/doi.org\/10.1371\/journal.pone.0066855.","journal-title":"PLoS ONE"},{"key":"2484_CR33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/(sici)1097-0258(19970228)16:4<385::aid-sim380>3.0.co;2-3","volume":"16","author":"R Tibshirani","year":"1997","unstructured":"Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med. 1997;16:385\u201395. https:\/\/doi.org\/10.1002\/(sici)1097-0258(19970228)16:4%3c385::aid-sim380%3e3.0.co;2-3.","journal-title":"Stat Med"},{"key":"2484_CR34","doi-asserted-by":"publisher","first-page":"5039","DOI":"10.1002\/cncr.26169","volume":"117","author":"MR Cooperberg","year":"2011","unstructured":"Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer. 2011;117:5039\u201346. https:\/\/doi.org\/10.1002\/cncr.26169.","journal-title":"Cancer"},{"key":"2484_CR35","doi-asserted-by":"publisher","first-page":"4192","DOI":"10.1200\/JCO.22.02511","volume":"41","author":"JS Parker","year":"2023","unstructured":"Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, Davies S, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2023;41:4192\u20139. https:\/\/doi.org\/10.1200\/JCO.22.02511.","journal-title":"J Clin Oncol"},{"key":"2484_CR36","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.freeradbiomed.2021.05.009","volume":"171","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Zhou H, Hua L, Hou C, Jia Q, Chen J, Zhang S, Wang Y, He S, Jia E. Verification of ferroptosis and pyroptosis and identification of PTGS2 as the hub gene in human coronary artery atherosclerosis. Free Radical Biol Med. 2021;171:55\u201368. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2021.05.009.","journal-title":"Free Radical Biol Med"},{"key":"2484_CR37","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.euo.2018.06.010","volume":"2","author":"F Giunchi","year":"2019","unstructured":"Giunchi F, Fiorentino M, Loda M. The metabolic landscape of prostate cancer. Eur Urol Oncol. 2019;2:28\u201336. https:\/\/doi.org\/10.1016\/j.euo.2018.06.010.","journal-title":"Eur Urol Oncol"},{"key":"2484_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14445","author":"AM Kulminski","year":"2024","unstructured":"Kulminski AM, Jain-Washburn E, Nazarian A, Wilkins HM, Veatch O, Swerdlow RH, Honea RoA. Association of APOE alleles and polygenic profiles comprising APOE-TOMM40-APOC1 variants with Alzheimer\u2019s disease neuroimaging markers. Alzheimer\u2019s & Dementia. 2024. https:\/\/doi.org\/10.1002\/alz.14445.","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"2484_CR39","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/bs.ai.2015.12.003","volume":"130","author":"S Spranger","year":"2016","unstructured":"Spranger S, Sivan A, Corrales L, Gajewski TF. Tumor and host factors controlling antitumor immunity and efficacy of cancer immunotherapy. Adv Immunol. 2016;130:75\u201393. https:\/\/doi.org\/10.1016\/bs.ai.2015.12.003.","journal-title":"Adv Immunol"},{"key":"2484_CR40","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1038\/emboj.2011.158","volume":"30","author":"CE Massie","year":"2011","unstructured":"Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, Warren A, et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 2011;30:2719\u201333. https:\/\/doi.org\/10.1038\/emboj.2011.158.","journal-title":"EMBO J"},{"key":"2484_CR41","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41467-023-36325-2","volume":"14","author":"T Hirz","year":"2023","unstructured":"Hirz T, Mei S, Sarkar H, Kfoury Y, Shulin Wu, Verhoeven BM, Subtelny AO, et al. Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses. Nat Commun. 2023;14:663. https:\/\/doi.org\/10.1038\/s41467-023-36325-2.","journal-title":"Nat Commun"},{"key":"2484_CR42","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40779-024-00526-7","volume":"11","author":"D-C Feng","year":"2024","unstructured":"Feng D-C, Zhu W-Z, Wang J, Deng-Xiong Li Xu, Shi QX, You J, et al. The implications of single-cell RNA-seq analysis in prostate cancer: unraveling tumor heterogeneity, therapeutic implications and pathways towards personalized therapy. Mil Med Res. 2024;11:21. https:\/\/doi.org\/10.1186\/s40779-024-00526-7.","journal-title":"Mil Med Res"},{"key":"2484_CR43","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/s41586-024-08290-3","volume":"637","author":"A Lyu","year":"2025","unstructured":"Lyu A, Fan Z, Clark M, Lea A, Luong D, Setayesh A, Starzinski A, et al. Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. Nature. 2025;637:1207\u201317. https:\/\/doi.org\/10.1038\/s41586-024-08290-3.","journal-title":"Nature"},{"key":"2484_CR44","doi-asserted-by":"publisher","first-page":"9949","DOI":"10.1038\/s41467-024-54364-1","volume":"15","author":"A Kiviaho","year":"2024","unstructured":"Kiviaho A, Eerola SK, Kallio HML, Andersen MK, Hoikka M, Tiihonen AM, Salonen I, et al. Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer. Nat Commun. 2024;15:9949. https:\/\/doi.org\/10.1038\/s41467-024-54364-1.","journal-title":"Nat Commun"},{"key":"2484_CR45","doi-asserted-by":"publisher","first-page":"e2305724","DOI":"10.1002\/advs.202305724","volume":"11","author":"X Bian","year":"2024","unstructured":"Bian X, Wang W, Abudurexiti M, Zhang X, Ma W, Shi G, Du L, et al. Integration analysis of single-cell multi-omics reveals prostate cancer heterogeneity. Adv Sci. 2024;11:e2305724. https:\/\/doi.org\/10.1002\/advs.202305724.","journal-title":"Adv Sci"},{"key":"2484_CR46","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.ccell.2023.02.004","volume":"41","author":"N Bancaro","year":"2023","unstructured":"Bancaro N, Cal\u00ec B, Troiani M, Elia AR, Arzola RA, Attanasio G, Lai P, et al. Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer. Cancer Cell. 2023;41:602-619.e11. https:\/\/doi.org\/10.1016\/j.ccell.2023.02.004.","journal-title":"Cancer Cell"},{"key":"2484_CR47","doi-asserted-by":"publisher","first-page":"6036","DOI":"10.1038\/s41467-022-33780-1","volume":"13","author":"HY Wong","year":"2022","unstructured":"Wong HY, Sheng Q, Hesterberg AB, Croessmann S, Rios BL, Giri K, Jackson J, et al. Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease. Nat Commun. 2022;13:6036. https:\/\/doi.org\/10.1038\/s41467-022-33780-1.","journal-title":"Nat Commun"},{"key":"2484_CR48","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1158\/0008-5472.CAN-20-3929","volume":"81","author":"SB Kemp","year":"2021","unstructured":"Kemp SB, Carpenter ES, Steele NG, Donahue KL, Nwosu ZC, Pacheco A, Velez-Delgado A, et al. Apolipoprotein E promotes immune suppression in pancreatic cancer through NF-\u03baB-mediated production of CXCL1. Can Res. 2021;81:4305\u201318. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-3929.","journal-title":"Can Res"},{"key":"2484_CR49","doi-asserted-by":"publisher","first-page":"5230","DOI":"10.7150\/ijbs.70117","volume":"18","author":"B Hui","year":"2022","unstructured":"Hui B, Chen Lu, Li H, Hao X, Liu H, Zhuo D, Wang Q, et al. Inhibition of APOE potentiates immune checkpoint therapy for cancer. Int J Biol Sci. 2022;18:5230\u201340. https:\/\/doi.org\/10.7150\/ijbs.70117.","journal-title":"Int J Biol Sci"},{"key":"2484_CR50","doi-asserted-by":"publisher","first-page":"2052658","DOI":"10.1080\/21645515.2022.2052658","volume":"18","author":"A Gozzetti","year":"2022","unstructured":"Gozzetti A, Ciofini S, Simoncelli M, Santoni A, Pacelli P, Raspadori D, Bocchia M. Anti CD38 monoclonal antibodies for multiple myeloma treatment. Hum Vaccin Immunother. 2022;18:2052658. https:\/\/doi.org\/10.1080\/21645515.2022.2052658.","journal-title":"Hum Vaccin Immunother"},{"key":"2484_CR51","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1093\/neuonc\/nos121","volume":"14","author":"A Levy","year":"2012","unstructured":"Levy A, Blacher E, Vaknine H, Lund FE, Stein R, Mayo L. CD38 deficiency in the tumor microenvironment attenuates glioma progression and modulates features of tumor-associated microglia\/macrophages. Neuro Oncol. 2012;14:1037\u201349. https:\/\/doi.org\/10.1093\/neuonc\/nos121.","journal-title":"Neuro Oncol"},{"key":"2484_CR52","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, Schrock A, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9:34. https:\/\/doi.org\/10.1186\/s13073-017-0424-2.","journal-title":"Genome Med"},{"key":"2484_CR53","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature12634","volume":"502","author":"C Kandoth","year":"2013","unstructured":"Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Charles Lu, Xie M, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502:333\u20139. https:\/\/doi.org\/10.1038\/nature12634.","journal-title":"Nature"},{"key":"2484_CR54","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1186\/s12935-021-02396-8","volume":"21","author":"HE Marei","year":"2021","unstructured":"Marei HE, Althani A, Afifi N, Hasan A, Caceci T, Pozzoli G, Morrione A, Giordano A, Cenciarelli C. p53 signaling in cancer progression and therapy. Cancer Cell Int. 2021;21:703. https:\/\/doi.org\/10.1186\/s12935-021-02396-8.","journal-title":"Cancer Cell Int"},{"key":"2484_CR55","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA. 2019;116:11428\u201336. https:\/\/doi.org\/10.1073\/pnas.1902651116.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2484_CR56","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson D, Van Allen EM, Yi-Mi Wu, Schultz N, Lonigro RJ, Mosquera J-M, Montgomery B, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215\u201328. https:\/\/doi.org\/10.1016\/j.cell.2015.05.001.","journal-title":"Cell"},{"key":"2484_CR57","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Ng AWT, Yang Wu, Boot A, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578:94\u2013101. https:\/\/doi.org\/10.1038\/s41586-020-1943-3.","journal-title":"Nature"},{"key":"2484_CR58","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12943-024-02137-1","volume":"23","author":"L Chen","year":"2024","unstructured":"Chen L, Yu-Xin Xu, Wang Y-S, Ren Y-Y, Xue-Man Dong PuWu, Xie T, Zhang Qi, Zhou J-L. Prostate cancer microenvironment: multidimensional regulation of immune cells, vascular system, stromal cells, and microbiota. Mol Cancer. 2024;23:229. https:\/\/doi.org\/10.1186\/s12943-024-02137-1.","journal-title":"Mol Cancer"},{"key":"2484_CR59","doi-asserted-by":"publisher","DOI":"10.1159\/000541881","author":"R Novysedlak","year":"2024","unstructured":"Novysedlak R, Guney M, Khouri MA, Bartolini R, Foley LK, Benesova I, Ozaniak A, et al. The immune microenvironment in prostate cancer: a comprehensive review. Oncology. 2024. https:\/\/doi.org\/10.1159\/000541881.","journal-title":"Oncology"},{"key":"2484_CR60","doi-asserted-by":"publisher","first-page":"e0301943","DOI":"10.1371\/journal.pone.0301943","volume":"19","author":"A Anton","year":"2024","unstructured":"Anton A, Hutchinson R, Hovens CM, Christie M, Ryan A, Gibbs P, Costello A, et al. An immune suppressive tumor microenvironment in primary prostate cancer promotes tumor immune escape. PLoS ONE. 2024;19:e0301943. https:\/\/doi.org\/10.1371\/journal.pone.0301943.","journal-title":"PLoS ONE"},{"key":"2484_CR61","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12894-023-01275-w","volume":"23","author":"B Yang","year":"2023","unstructured":"Yang B, Jiang Y, Yang J, Zhou W, Yang T, Zhang R, Jinming Xu, Guo H. Characterization of metabolism-associated molecular patterns in prostate cancer. BMC Urol. 2023;23:104. https:\/\/doi.org\/10.1186\/s12894-023-01275-w.","journal-title":"BMC Urol"},{"key":"2484_CR62","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1007\/s00345-020-03497-1","volume":"39","author":"I Tsaur","year":"2021","unstructured":"Tsaur I, Brandt MP, Juengel E, Manceau C, Ploussard G. Immunotherapy in prostate cancer: new horizon of hurdles and hopes. World J Urol. 2021;39:1387\u2013403. https:\/\/doi.org\/10.1007\/s00345-020-03497-1.","journal-title":"World J Urol"},{"key":"2484_CR63","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1126\/scitranslmed.adg3049","volume":"15","author":"J Li","year":"2023","unstructured":"Li J, Liu J, Zhou Z, Wu R, Chen X, Yu C, Stockwell B, Kroemer G, Kang R, Tang D. Tumor-specific GPX4 degradation enhances ferroptosis-initiated antitumor immune response in mouse models of pancreatic cancer. Sci Transl Med. 2023;15:3049. https:\/\/doi.org\/10.1126\/scitranslmed.adg3049.","journal-title":"Sci Transl Med"},{"key":"2484_CR64","doi-asserted-by":"publisher","first-page":"1255443","DOI":"10.3389\/fimmu.2023.1255443","volume":"14","author":"Z Lin","year":"2023","unstructured":"Lin Z, Zou S, Wen K. The crosstalk of CD8+ T cells and ferroptosis in cancer. Front Immunol. 2023;14:1255443. https:\/\/doi.org\/10.3389\/fimmu.2023.1255443.","journal-title":"Front Immunol"},{"key":"2484_CR65","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.urology.2009.05.016","volume":"74","author":"C Nabhan","year":"2009","unstructured":"Nabhan C, Lestingi TM, Galvez A, Tolzien K, Kelby SK, Tsarwhas D, Newman S, Bitran JD. Erlotinib has moderate single-agent activity in chemotherapy-na\u00efve castration-resistant prostate cancer: final results of a phase II trial. Urology. 2009;74:665\u201371. https:\/\/doi.org\/10.1016\/j.urology.2009.05.016.","journal-title":"Urology"},{"key":"2484_CR66","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/1471-2407-7-142","volume":"7","author":"M Gross","year":"2007","unstructured":"Gross M, Higano C, Pantuck A, Castellanos O, Green E, Nguyen K, Agus DB. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer. 2007;7:142. https:\/\/doi.org\/10.1186\/1471-2407-7-142.","journal-title":"BMC Cancer"},{"key":"2484_CR67","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00775-022-01971-2","volume":"28","author":"ML Matlou","year":"2023","unstructured":"Matlou ML, Malan FP, Nkadimeng S, McGaw L, Tembu VJ, Manicum A-L. Exploring the in vitro anticancer activities of Re(I) picolinic acid and its fluorinated complex derivatives on lung cancer cells: a structural study. J Biol Inorg Chem. 2023;28:29\u201341. https:\/\/doi.org\/10.1007\/s00775-022-01971-2.","journal-title":"J Biol Inorg Chem"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02484-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02484-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02484-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T06:53:51Z","timestamp":1748847231000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02484-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2484"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02484-5","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"assertion":[{"value":"11 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been updated to correct an affiliation.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not available, for the study used only public database samples and did not involve collecting human or animal specimens for experiments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"744"}}